
ARPA-H Commits $160 Million to Make Bespoke Gene Editing Drugs Routine for Rare Diseases
The U.S. Advanced Research Projects Agency for Health (ARPA-H) announced July 9 that it will commit up to $160 million over five years to develop a new model for treating rare genetic diseases: custom, in vivo gene editing drugs made for individual patients or small groups sharing the same mutation. The program, called THRIVE (Treating […]










